Results 181 to 190 of about 1,029 (201)

Critical care management of chimeric antigen receptor T‐cell therapy recipients

Ca-A Cancer Journal for Clinicians, 2022
Alexander Shimabukuro-Vornhagen, Boris Böll, Victoria Metaxa   +2 more
exaly  

AKT2 is a downstream target of metabotropic glutamate receptor 1 (Grm1).

Pigment cell & melanoma research, 2010
We reported earlier on the oncogenic properties of Grm1 by demonstrating that stable Grm1-mouse-melanocytic clones proliferate in the absence of growth supplement and anchorage in vitro. In addition, these clones also exhibit aggressive tumorigenic phenotypes in vivo with short latency in tumor formation in both immunodeficient and syngeneic mice.
Seung-Shick, Shin, Brian A, Wall, James S, Goydos, Suzie, Chen   +3 more
openaire   +1 more source

Breast Cancer Statistics, 2022

Ca-A Cancer Journal for Clinicians, 2022
Hyuna Sung, Kimberly D Miller, Rebecca L Siegel   +2 more
exaly  

Current treatment and recent progress in gastric cancer

Ca-A Cancer Journal for Clinicians, 2021
Smita S Joshi, Brian D Badgwell
exaly  

Glutamate receptor, metabotropic, type 1

AfCS-Nature Molecule Pages, 2005
openaire   +1 more source

Metabotropic Glutamate Receptor 1

2020
openaire   +1 more source

A review of cancer immunotherapy toxicity

Ca-A Cancer Journal for Clinicians, 2020
Lucy Boyce Kennedy
exaly  

Treatment of muscle‐invasive and advanced bladder cancer in 2020

Ca-A Cancer Journal for Clinicians, 2020
Vaibhav G Patel, William K Oh, Matthew D Galsky   +2 more
exaly  

Breast cancer statistics, 2019

Ca-A Cancer Journal for Clinicians, 2019
Carol E Desantis, Jiemin, Mia M Gaudet
exaly  

Evolving standards of care and new challenges in the management of HER2‐positive breast cancer

Ca-A Cancer Journal for Clinicians, 2020
Grace M Choong, Grace D Cullen, Ciara C O'sullivan   +2 more
exaly